The companies signed a series of agreements for the development, manufacturing and commercialization of infectious disease diagnostic products.
As per terms of the deals, the companies will develop rapid infectious disease tests by using the patented NOWDx ADEXUSDx test system.
The deal will also allow NOWDx to produce existing Zalgen products, including ReEBOV antigen rapid test for Ebola virus and ReLASV antigen rapid test for Lassa fever.
ReEBOV antigen rapid test is the first immunoassay, which was authorized by FDA for emergency use for the presumptive detection of Ebola virus.
It is also listed for procurement by the World Helath Organization (WHO) under the Emergency Use Assessment and Listing procedure.
Zalgen is a partner of the Viral Hemorrhagic Fever Consortium (VHFC), an academic and industry partnership lead by Tulane University. It is involved in the development of advanced diagnostic and immunotherapeutic products for biothreat agents and emerging pathogens.
Zalgen managing director Dr Luis Branco said: “The new alliance with NOWDiagnostics significantly enhances our diagnostic product capability worldwide.
“Zalgen and the VHFC plan to continue building on our portfolio of diagnostic products for hemorrhagic fevers and other tropical diseases, and the ADEXUSDx cassette is the ideal immunodiagnostic platform to address the market demands.”
NOWDiagnostics CEO Kevin Clark said: “High risk diseases have a devastating impact on communities across the globe. We are excited to leverage VHFC’s world-class science with our platform to try and address the need for fast and accurate diagnoses, even in the remotest of places.”
